Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era
Purpose of Review
The purpose of this review is to summarize the prevalence and clinical implications of the isolated anti-HBc serologic profile in HIV-infected individuals. We highlight the rare but important issue of HBV reactivation in the setting of HCV therapy and describe an approach to management.
The isolated anti-HBc pattern, a profile that most often indicates past exposure to HBV with waning anti-HBs immunity, is found commonly in HIV-infected individuals, particularly those with HCV. Some large cohort studies demonstrate an association with advanced liver disease, while others do not. Conversely, meta-analyses have found an association between occult HBV infection (a component of the isolated anti-HBc pattern) and advanced liver disease and hepatocellular carcinoma in HIV-uninfected individuals. In HIV-uninfected individuals with anti-HBc positivity, HBV reactivation has been reported in patients receiving HCV therapy. This phenomenon is likely the result of disinhibition of HBV with HCV eradication.
In HIV-infected patients, the long-term liver outcomes associated with the isolated anti-HBc pattern remain to be fully elucidated, supporting the need for large cohort studies with longitudinal follow-up. HBV reactivation during HCV DAA therapy has been well-described in HIV-uninfected cohorts and can inform algorithms for the screening and management of the isolated anti-HBc pattern in this population.
KeywordsDAA HCV treatment Isolated anti-HBc Occult HBV HIV/HCV HIV infection
Compliance with Ethical Standards
Conflict of Interest
Debika Bhattacharya collaborated on an NIH sponsored protocol involving Merck, BMS, Abbvie, and Sanofi.
Jennifer J. Chang and Neaka Mohtashemi declare that they have no competing interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 1.Bhattacharya D, Tseng CH, Tate JP, et al. Isolated hepatitis B Core antibody is associated with advanced hepatic fibrosis in HIV/HCV infection but not in HIV infection alone. J Acquir Immune Defic Syndr. 2016;72(1):e14–7. https://doi.org/10.1097/QAI.0000000000000941.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Palacios R, Mata R, Hidalgo A, et al. Very low prevalence and no clinical significance of occult hepatitis B in a cohort of HIV-infected patients with isolated anti-HBc seropositivity: the BHOI study. HIV Clin Trials. 2008;9(5):337–40. https://doi.org/10.1310/hct0905-337.CrossRefPubMedGoogle Scholar
- 10.Khamduang W, Ngo-Giang-Huong N, Gaudy-Graffin C, et al. Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women. Clin Infect Dis. 2013;56(12):1704–12. https://doi.org/10.1093/cid/cit166.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.French AL, Hotton A, Young M, et al. Isolated hepatitis B Core antibody status is not associated with accelerated liver disease progression in HIV/hepatitis C coinfection. J Acquir Immune Defic Syndr. 2016;72(3):274–80. https://doi.org/10.1097/QAI.0000000000000969.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative south African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital. J Med Virol. 2009;81(3):406–12. https://doi.org/10.1002/jmv.21418.CrossRefPubMedGoogle Scholar
- 21.Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20(9):1253–60. https://doi.org/10.1097/01.aids.0000232232.41877.2a.CrossRefPubMedGoogle Scholar
- 31.Lok AS, Everhart JE, Di Bisceglie AM, et al. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54(2):434–42. https://doi.org/10.1002/hep.24257.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol. 2001;63(3):220–7.CrossRefPubMedGoogle Scholar
- 37.Jongjirawisan Y, Ungulkraiwit P, Sungkanuparph S. Isolated antibody to hepatitis B core antigen in HIV-1 infected patients and a pilot study of vaccination to determine the anamnestic response. J Med Assoc Thail. 2006;89(12):2028–34.Google Scholar
- 40.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. August 2017. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/344/hbv.
- 41.Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system. Ann Intern Med. 2017;166(11):792–8. https://doi.org/10.7326/M17-0377.CrossRefPubMedGoogle Scholar
- 50.Fabbri G, Mastrorosa I, Vergori A, et al. Reactivation of occult HBV infection in an HIV/HCV co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. BMC Infect Dis. 2017;17(1):182. https://doi.org/10.1186/s12879-017-2287-y.CrossRefPubMedPubMedCentralGoogle Scholar
- 51.Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164. https://doi.org/10.1186/s13256-015-0630-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Hayashi K, Ishigami M, Ishizu Y, et al. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis? Clin J Gastroenterol. 2016;9(4):252–6. https://doi.org/10.1007/s12328-016-0657-4.CrossRefPubMedGoogle Scholar
- 56.Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34(2):404–10. https://doi.org/10.1053/jhep.2001.26511.CrossRefPubMedGoogle Scholar
- 62.AASLD/IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. April 2017. www.hcvguidelines.org.
- 63.VA HIV, Hepatitis, and Public Health Pathogens Program. Recommendations for Hepatitis B Viral Infection Testing and Monitoring among HCV-Infected Veterans Being Considered for DAA Treatment. October 2016. https://www.hepatitis.va.gov/pdf/hbv-recommendations-hcv-daa-treatment.pdf.